RT @CD_AACR: ICYMI: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase 2 study evaluating an individualized trea…
RT @CD_AACR: ICYMI: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase 2 study evaluating an individualized trea…
RT @CD_AACR: ICYMI: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase 2 study evaluating an individualized trea…
RT @CD_AACR: ICYMI: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase 2 study evaluating an individualized trea…
ICYMI: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase 2 study evaluating an individualized treatment strategy for metastatic disease. @DocCatenacci @UCCancerCenter #ClinicalTrial #GastricCancer #EsophagealCancer https://t.c
RT @ElizSMcKenna: ICYMI: the PANGEA trial - mentioned in this week’s @OncoAlert weekly roundup: https://t.co/hOdADzmVvA
RT @ElizSMcKenna: ICYMI: the PANGEA trial - mentioned in this week’s @OncoAlert weekly roundup: https://t.co/hOdADzmVvA https://t.co/dRvUzg…
RT @ElizSMcKenna: ICYMI: the PANGEA trial - mentioned in this week’s @OncoAlert weekly roundup: https://t.co/hOdADzmVvA https://t.co/dRvUzg…
ICYMI: the PANGEA trial - mentioned in this week’s @OncoAlert weekly roundup: https://t.co/hOdADzmVvA
Novel treatment schema and trial design. This is what finding the signal looks like. Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study @CD_AACR @SWOG @DavendraSohal @CathyEngMD https://t.co/9VqjHC9Wbt
RT @NatRevClinOncol: In the personalized antibodies for gastroesophageal adenocarcinoma (PANGEA), involving individualized treatment with…
Promising #clinicaltrial results using a personalized treatment strategy applied at 1st diagnosis then serially over up to 3 treatmt lines using monoclonal antibodies combined w/optimally-sequenced chemo for patients w/ #metastatic gastroesophageal adenoca
RT @NatRevClinOncol: In the personalized antibodies for gastroesophageal adenocarcinoma (PANGEA), involving individualized treatment with…
RT @NatRevClinOncol: In the personalized antibodies for gastroesophageal adenocarcinoma (PANGEA), involving individualized treatment with…
In the personalized antibodies for gastroesophageal adenocarcinoma (PANGEA), involving individualized treatment with mAb & optimally-sequenced chemotherapy serially over up to 3 lines, 1-yr OS was 66% & mOS was 15.7 months, meeting the primary end
RT @RussellPetty19: Intra-patient heterogeneity in gastroesophageal adenocarcinoma is a major therapeutic barrier.This groundbreaking,tho…
RT @ElizSMcKenna: Just out in @CD_AACR: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an…
RT @benweinbergmd: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA) - excellent work by @DocCatenacci and colleagues @U…
RT @LizzySmyth1: Great work in @CD_AACR from @DocCatenacci on the PANGEA trial of personalised targeted therapy for #stomachcancer and #es…
RT @CD_AACR: Just published #OnlineFirst: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating…
RT @benweinbergmd: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA) - excellent work by @DocCatenacci and colleagues @U…
RT @benweinbergmd: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA) - excellent work by @DocCatenacci and colleagues @U…
RT @LizzySmyth1: Great work in @CD_AACR from @DocCatenacci on the PANGEA trial of personalised targeted therapy for #stomachcancer and #es…
RT @alan_burguete: Congratulations to the authors! A step forward towards personalised medicine for our patients with GEA cancers! 👏🏻👏🏻 @Do…
Congratulations to the authors! A step forward towards personalised medicine for our patients with GEA cancers! 👏🏻👏🏻 @DocCatenacci
RT @LizzySmyth1: Great work in @CD_AACR from @DocCatenacci on the PANGEA trial of personalised targeted therapy for #stomachcancer and #es…
RT @LizzySmyth1: Great work in @CD_AACR from @DocCatenacci on the PANGEA trial of personalised targeted therapy for #stomachcancer and #es…
RT @ElizSMcKenna: Just out in @CD_AACR: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an…
RT @LizzySmyth1: Great work in @CD_AACR from @DocCatenacci on the PANGEA trial of personalised targeted therapy for #stomachcancer and #es…
RT @LizzySmyth1: Great work in @CD_AACR from @DocCatenacci on the PANGEA trial of personalised targeted therapy for #stomachcancer and #es…
RT @ElizSMcKenna: Just out in @CD_AACR: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an…
Adapting each therapy to each patient, that’s the step forward https://t.co/NjfcA5dAc1
RT @benweinbergmd: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA) - excellent work by @DocCatenacci and colleagues @U…
RT @LizzySmyth1: Great work in @CD_AACR from @DocCatenacci on the PANGEA trial of personalised targeted therapy for #stomachcancer and #es…
RT @benweinbergmd: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA) - excellent work by @DocCatenacci and colleagues @U…
RT @RussellPetty19: Intra-patient heterogeneity in gastroesophageal adenocarcinoma is a major therapeutic barrier.This groundbreaking,tho…
RT @ElizSMcKenna: Just out in @CD_AACR: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an…
An elegant proof of concept in #gastroesophageal cancers.
RT @LizzySmyth1: Great work in @CD_AACR from @DocCatenacci on the PANGEA trial of personalised targeted therapy for #stomachcancer and #es…
RT @LizzySmyth1: Great work in @CD_AACR from @DocCatenacci on the PANGEA trial of personalised targeted therapy for #stomachcancer and #es…
Great work in @CD_AACR from @DocCatenacci on the PANGEA trial of personalised targeted therapy for #stomachcancer and #esophagealcancer. ✅ This is the way forward for trial design in small biomarker selected groups. @OncoAlert @mery80878696 @RussellPet
RT @RussellPetty19: Intra-patient heterogeneity in gastroesophageal adenocarcinoma is a major therapeutic barrier.This groundbreaking,tho…
RT @CD_AACR: Just published #OnlineFirst: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating…
RT @RussellPetty19: Intra-patient heterogeneity in gastroesophageal adenocarcinoma is a major therapeutic barrier.This groundbreaking,tho…
RT @ElizSMcKenna: Just out in @CD_AACR: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an…
Awesome. I really like this concept much more than "let's sell immmunotherapy to everyone regardless whether it works"
RT @RussellPetty19: Intra-patient heterogeneity in gastroesophageal adenocarcinoma is a major therapeutic barrier.This groundbreaking,tho…
RT @benweinbergmd: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA) - excellent work by @DocCatenacci and colleagues @U…
RT @benweinbergmd: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA) - excellent work by @DocCatenacci and colleagues @U…
RT @CD_AACR: Just published #OnlineFirst: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating…
RT @RussellPetty19: Intra-patient heterogeneity in gastroesophageal adenocarcinoma is a major therapeutic barrier.This groundbreaking,tho…
RT @ElizSMcKenna: Just out in @CD_AACR: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an…
Intra-patient heterogeneity in gastroesophageal adenocarcinoma is a major therapeutic barrier.This groundbreaking,thought provoking and innovative precision medicine clinical trial provides a way for us to move forward. This is good data and great work
RT @ElizSMcKenna: Just out in @CD_AACR: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an…
RT @ElizSMcKenna: Just out in @CD_AACR: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an…
RT @ElizSMcKenna: Just out in @CD_AACR: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an…
RT @ElizSMcKenna: Just out in @CD_AACR: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an…
RT @ElizSMcKenna: Just out in @CD_AACR: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an…
RT @CD_AACR: Just published #OnlineFirst: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating…
Just published #OnlineFirst: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an individualized treatment strategy for metastatic disease. @DocCatenacci @UCCancerCenter #ClinicalTrial #EsophagealCancer https
RT @KlempnerSam: Definitely a must read. Look forward to advancing this paradigm. #GEAwesome @DocCatenacci @OncoAlert https://t.co/1zTMr91…
RT @benweinbergmd: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA) - excellent work by @DocCatenacci and colleagues @U…
Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA) - excellent work by @DocCatenacci and colleagues @UCCancerCenter https://t.co/PDgy6lTenr
RT @KlempnerSam: Definitely a must read. Look forward to advancing this paradigm. #GEAwesome @DocCatenacci @OncoAlert https://t.co/1zTMr91…
Definitely a must read. Look forward to advancing this paradigm. #GEAwesome @DocCatenacci @OncoAlert
Just out in @CD_AACR: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an individualized treatment strategy for metastatic disease @DocCatenacci @UCCancerCenter #ClinicalTrial #GastricCancer #EsophagealCancer